GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

The pharmaceutical intermediates market is estimated to be valued at USD 43.67 billion in 2024 and is expected to reach USD 75.12 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2031.

The pharmaceutical intermediates market has been witnessing significant growth over the past few years. Pharmaceutical intermediates are chemical compounds produced during the various steps of pharmaceutical drug synthesis. They help in efficiently manufacturing drugs in large quantities with minimum resources. Rising prevalence of chronic diseases along with increasing R&D investments by pharmaceutical companies are fueling the demand for intermediates. Additionally, the growing geriatric population worldwide prone to chronic medical conditions is positively influencing the market growth. However, strict regulatory frameworks for the approval of new intermediates and high capital requirement for setting up manufacturing facilities are some challenges restraining the market growth. Overall, the widespread use of intermediates in streamlining drug production processes indicates huge opportunities for market expansion in the coming years.

Market Dynamics:

The global pharmaceutical intermediates market is primarily driven by the growing incidence of lifestyle-induced chronic diseases like diabetes, cancer, cardiovascular disorders, etc. Favorable government policies supporting local drug manufacturing is another key factor pushing the market growth. On the other hand, factors like high R&D costs associated with developing novel intermediates and lengthy approval times from regulatory bodies are slowing the market progress. Also, intense competition among established players poses major challenge to new entrants. However, rising pharmaceutical outsourcing trends from developing countries present lucrative opportunities for market players. Continued technological innovations to develop safe and eco-friendly intermediates will further support the market expansion over the forecast period.

Key Features of the Study:

• This report provides an in-depth analysis of the global pharmaceutical intermediates market, and provides market size (USD Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global pharmaceutical intermediates market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• The key companies covered as a part of this study include Evonik, Borregaard AS, Sudarshan Pharma, A.R. Life Science, Actylis, Saurav Chemicals Ltd., Lianhetech, Midas Pharma GmbH, Sanofi , BASF SE, Chiracon GmbH, Lonza, Chemcon Speciality Chemicals Limited., Modepro India Pvt. Ltd., Lifechem Pharma, Sarex, and LANXESS.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global pharmaceutical intermediates market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pharmaceutical intermediates market.

Detailed Segmentation:

• Intermediate Type:
  • Bulk Intermediate
  • Chemical Intermediate
• Application:
  • Anti-Infective Drugs
  • Analgesics
  • Antidiabetic Drugs
  • Cardiovascular Drugs
  • Antimicrobial Drugs
  • Anti-inflammatory Drugs
  • Others
• End User:
  • Biopharmaceutical Companies
  • CMO
  • CRO
  • Others
• Region: 
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Evonik
  • Borregaard AS
  • Sudarshan Pharma
  • R. Life Science
  • Actylis
  • Saurav Chemicals Ltd.
  • Lianhetech
  • Midas Pharma GmbH
  • Sanofi
  • BASF SE
  • Chiracon GmbH
  • Lonza
  • Chemcon Speciality Chemicals Limited.
  • Modepro India Pvt. Ltd.
  • Lifechem Pharma
  • Sarex
  • LANXESS